Back

Celldex keeps Buy rating as LifeSci Capital sets $64 price target

Verifying
  • Sam Slutsky maintained a Buy rating on Celldex and set a $64 price target.
  • Celldex reported $22 thousand in quarterly revenue and a $73.5 million GAAP net loss.
  • Goldman Sachs maintained Hold on September 22, while H.C. Wainwright issued Buy yesterday.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.